End-stage Heart Failure with COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV
Publication date: Available online 7 April 2020Source: JACC: Heart FailureAuthor(s): Nianguo Dong, Jie Cai, Ying Zhou, Junwei Liu, Fei Li
The presence of cardiovascular co-morbidities and the known effects of coronaviruses on the cardiovascular system have called attention to the potential implications for patients with cardiovascular risk factors. This evidence-based viewpoint will address two questions: (a) are individuals with underlying cardiovascular risk factors (e.g. high blood pressure or diabetes) or overt disease (e.g. coronary heart disease, heart failure, kidney disease) more likely to develop severe Covid-19 and to die than those without underlying conditions? (b) does the regular use of angiotensin-converting enzyme inhibitors (ACE-i) or angiot...
This article is protected by copyright. All rights reserved.
NEW BRUNSWICK, NJ, May 27, 2020 — The Janssen Pharmaceutical Companies of Johnson &Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new pediatric formulation of SIRTURO® (bedaquiline). SIRTURO® is now indicated for use as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multidrug-resistant tuberculosis (MDR‑TB). In the U.S., the medicine should be reserved for use when an effective treatment regimen cannot otherwise be provided. This indication received accelera...
AbstractCoronavirus diseases 2019 (COVID-19) has become a worldwide pandemic affecting people at high risk and particularly at advanced age, cardiovascular and pulmonary disease. As cardiovascular patients are at high risk but also have dyspnea and fatigue as leading symptoms, prevention, diagnostics and treatment in these patients are important to provide adequate care for those with or without COVID-19 but most importantly when comorbid cardiovascular conditions are present. Severe COVID-19 with acute respiratory distress (ARDS) is challenging as patients with elevated myocardial markers such as troponin are at enhanced ...
Publication date: June 2020Source: JACC: Heart Failure, Volume 8, Issue 6Author(s): Christopher M. O’Connor
Publication date: June 2020Source: JACC: Heart Failure, Volume 8, Issue 6Author(s): Nianguo Dong, Jie Cai, Ying Zhou, Junwei Liu, Fei Li
Conditions: ARDS Related to Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 2; Acute Refractory Heart Failure Related to SARS-CoV 2 Intervention: Sponsor: Rennes University Hospital Recruiting
This Viewpoint discusses the need for new payment models to incentivize innovations in personalized home care and facilitate transitions already occurring in response to the COVID-19 pandemic, and to develop lower-cost higher-quality approaches to home-based management of chronic illnesses such as heart failure and Parkinson disease.
European Journal of Heart Failure, Accepted Article.
Publication date: Available online 19 May 2020Source: JACC: Heart FailureAuthor(s): Marc Bonnet, Fabien Craighero, Brahim Harbaoui